

## FORM 3

UNITED STATES SECURITIES AND EXCHANGE  
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES

## OMB APPROVAL

OMB Number: 3235-0104  
 Estimated average burden  
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Choong Ingrid</u> <hr/> (Last) (First) (Middle) C/O EIGER BIOPHARMACEUTICALS, INC. 2155 PARK BLVD. <hr/> (Street) PALO CA 94306 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/30/2023	3. Issuer Name and Ticker or Trading Symbol <u>Eiger BioPharmaceuticals, Inc.</u> [ EIGR ] <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Business Officer <hr/> 5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	31,100 <sup>(1)</sup>	D	
Common Stock	2,400	I	By Family Trust <sup>(2)</sup>

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(3)	09/23/2023	Common Stock	5,251	1.37	D	
Stock Option (Right to Buy)	(3)	08/28/2026	Common Stock	7,490	15.89	D	
Stock Option (Right to Buy)	(3)	03/08/2027	Common Stock	13,200	11.75	D	
Stock Option (Right to Buy)	(3)	03/13/2028	Common Stock	25,000	9.5	D	
Stock Option (Right to Buy)	(3)	03/20/2029	Common Stock	17,500	14.31	D	
Stock Option (Right to Buy)	(4)	09/29/2029	Common Stock	10,000	10.25	D	
Stock Option (Right to Buy)	(5)	03/11/2030	Common Stock	35,000	5.6	D	
Stock Option (Right to Buy)	(6)	03/11/2031	Common Stock	60,000	9.99	D	
Stock Option (Right to Buy)	(7)	07/28/2031	Common Stock	17,500	8.15	D	
Stock Option (Right to Buy)	(8)	03/10/2032	Common Stock	98,000	5.1	D	
Stock Option (Right to Buy)	(9)	01/25/2033	Common Stock	25,750	1.37	D	
Stock Option (Right to Buy)	(10)	02/28/2033	Common Stock	98,000	1.71	D	

## Explanation of Responses:

1. Includes 3,333 shares underlying Restricted Stock Units ("RSUs") award that will vest in three equal annual installments measured from March 12, 2021, and 10,666 shares underlying RSUs award that will vest in three equal annual installments measured from March 11, 2022.

2. These shares are held directly by the Choong-Dragoli Family Trust, for which the Reporting Person serves as co-trustee.

3. These options are fully vested.

4. The option vests in equal installments over 48 months measured from September 30, 2019, subject to the Reporting Person's continuous service as of each such date.

5. The option vests in equal installments over 48 months measured from March 12, 2020, subject to the Reporting Person's continuous service as of each such date.
6. The option vests in equal installments over 48 months measured from March 12, 2021, subject to the Reporting Person's continuous service as of each such date.
7. The option vests in equal installments over 36 months measured from July 29, 2021, subject to the Reporting Person's continuous service as of each such date.
8. The option vests in equal installments over 48 months measured from March 11, 2022, subject to the Reporting Person's continuous service as of each such date.
9. The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer.
10. The option vests in equal installments over 48 months measured from March 1, 2023, subject to the Reporting Person's continuous service as of each such date.

## Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ James Vollins,  
Attorney-in-Fact for Ingrid 09/05/2023  
C. Choong

\*\* Signature of Reporting Person \_\_\_\_\_ Date \_\_\_\_\_

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints James Vollins of Eiger BioPharmaceuticals, Inc. (the “**Company**”), as the undersigned’s true and lawful attorney-in-fact and agent to:

(1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the Securities and Exchange Commission (the “**SEC**”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation thereunder (including SEC Forms 3, 4 and 5, amendments thereto and joint filing agreements in connection therewith) (the “Section 16 Reports”) and forms required by Rule 144 under the Securities Act of 1933 (the “Forms 144”);

(2) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the SEC all Section 16 Reports in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Section 16 Reports and Forms 144, and file such Forms with the SEC and any stock exchange, self-regulatory association or any other authority; and

(4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact’s discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, or such attorney-in-fact's substitute or substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144 under the Securities Act of 1933.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file neither Section 16 Reports nor Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the attorney-in-fact. This Power of Attorney revokes any other power of attorney that the undersigned has previously granted to representatives of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Dated: 8/30/23

/s/ Ingrid Choong  
Ingrid Choong